Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/08/24
End: 12/12/26
Due: 12/12/27
Phase: N/A
Priority: Normal
Start: 08/29/22
End: 12/31/27
Due: 12/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | NCT06667141 | Acrivon Therapeutics | user2@example.com | None | 2024-10-08 | 2026-12-12 | 2027-12-12 | - | - | 2025-07-14 |
| A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | NCT05548296 | Acrivon Therapeutics | user2@example.com | None | 2022-08-29 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |